Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.22.2.2
Commitments and Contingencies (Details Narrative)
 3 Months Ended 6 Months Ended
Feb. 07, 2022
USD ($)
Nov. 19, 2021
ft²
Mar. 26, 2021
USD ($)
Oct. 05, 2020
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Loss Contingencies [Line Items]                
Litigation settlement expense $ 425,000              
Project fee             $ 2,100,000  
Recorded expenses         $ 192,000,000,000   383,000,000,000  
Other commitments, description       On October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products for use in clinical trials. At June 30, 2022, the Company’s commitments in relation to these Statements of Work and any related Change Orders totaled approximately $13.0 million, of which $9.8 million was incurred at that date and an additional $3.2 million is in process during fiscal year 2022.        
Research and development expense         1,139,000 $ 639,000 3,226,000 $ 2,279,000
Rent expense         29,000   58,000  
Aimmune Therapeutics Inc [Member]                
Loss Contingencies [Line Items]                
Area of land | ft²   4,500            
Commencement date   commencement date of January 1, 2022 and maturing on June 30, 2024            
Master Services Agreement [Member] | Cytovance Biologics, Inc. [Member]                
Loss Contingencies [Line Items]                
Commitment amount for services, total             13,000,000.0  
Commitment cost incurred             9,800,000  
Compensation cost expected to be incurred in future             3,200,000  
Research And Development Agreements [Member]                
Loss Contingencies [Line Items]                
Research and development expense         92,000,000   1,180,000,000  
2016 Patent License Agreement [Member]                
Loss Contingencies [Line Items]                
Proceeds from upfront amount         200,000   200,000  
Maintanance fee             $ 100,000  
Royalty fee percentage             0.04  
Performance milestone payments             $ 3,100,000  
Sales milestone payments             1,000,000.0  
Gross sales             250,000,000  
Sales revenue             5,000,000.0  
Cummulative gross sales             500,000,000  
2016 Patent License Agreement [Member] | Minimum [Member]                
Loss Contingencies [Line Items]                
Annual royalty payments             250,000  
2016 Patent License Agreement [Member] | Maximum [Member]                
Loss Contingencies [Line Items]                
Annual royalty payments             5,000,000.0  
2016 Exclusive Patent License Agreement [Member]                
Loss Contingencies [Line Items]                
Research and development expense         0   0  
2021 Patent License Agreement [Member]                
Loss Contingencies [Line Items]                
Research and development expense         0   0  
Annual royalty payments             250,000  
Performance milestone payments             3,100,000  
Sales milestone payments             1,000,000.0  
Gross sales             250,000,000  
Sales revenue             5,000,000.0  
Cummulative gross sales             500,000,000  
Upfront license fee     $ 20,000          
License maintenance fee, receivable         $ 5,000   5,000  
Maintanance fee             $ 2,000,000.0  
2021 Patent License Agreement [Member] | Minimum [Member]                
Loss Contingencies [Line Items]                
Net sales percentage             0.025  
2021 Patent License Agreement [Member] | Maximum [Member]                
Loss Contingencies [Line Items]                
Net sales percentage             0.05